Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.

  title={Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.},
  author={Philip J Mease and Mark C Genovese and Maria Greenwald and Christopher T. Ritchlin and Andr{\'e} D. Beaulieu and Atul A Deodhar and Richard A. Newmark and Jingyuan Feng and Ngozi E. Erondu and Ajay Nirula},
  journal={The New England journal of medicine},
  volume={370 24},
BACKGROUND We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthritis. METHODS We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. At week 12, patients who had not discontinued their participation in the… CONTINUE READING